Van Eck Associates Cut Its Seattle Genetics (SGEN) Holding; Alyeska Investment Group LP Upped Paylocity Hldg (PCTY) Holding

February 15, 2018 - By Hazel Jackson

Van Eck Associates Corp decreased Seattle Genetics Inc (SGEN) stake by 13.81% reported in 2017Q3 SEC filing. Van Eck Associates Corp sold 29,081 shares as Seattle Genetics Inc (SGEN)’s stock rose 1.68%. The Van Eck Associates Corp holds 181,469 shares with $9.87 million value, down from 210,550 last quarter. Seattle Genetics Inc now has $8.48 billion valuation. The stock increased 0.92% or $0.5 during the last trading session, reaching $54.56. About 408,575 shares traded. Seattle Genetics, Inc. (NASDAQ:SGEN) has risen 75.68% since February 15, 2017 and is uptrending. It has outperformed by 58.98% the S&P500.

Alyeska Investment Group Lp increased Paylocity Hldg Corp (PCTY) stake by 56.25% reported in 2017Q3 SEC filing. Alyeska Investment Group Lp acquired 225,000 shares as Paylocity Hldg Corp (PCTY)’s stock rose 21.12%. The Alyeska Investment Group Lp holds 625,000 shares with $30.51M value, up from 400,000 last quarter. Paylocity Hldg Corp now has $2.36B valuation. The stock increased 1.37% or $0.606 during the last trading session, reaching $44.936. About 122,568 shares traded. Paylocity Holding Corporation (NASDAQ:PCTY) has risen 26.16% since February 15, 2017 and is uptrending. It has outperformed by 9.46% the S&P500.

Van Eck Associates Corp increased National Oilwell Varco Inc (NYSE:NOV) stake by 182,639 shares to 1.83M valued at $65.36M in 2017Q3. It also upped Starbucks Corp (NASDAQ:SBUX) stake by 54,522 shares and now owns 566,143 shares. Gold Standard Ventures Corp (NYSEMKT:GSV) was raised too.

Among 18 analysts covering Seattle Genetics (NASDAQ:SGEN), 9 have Buy rating, 0 Sell and 9 Hold. Therefore 50% are positive. Seattle Genetics had 64 analyst reports since July 31, 2015 according to SRatingsIntel. The company was maintained on Tuesday, August 25 by William Blair. As per Thursday, February 4, the company rating was initiated by Barclays Capital. The rating was maintained by H.C. Wainwright with “Buy” on Monday, June 19. As per Friday, October 27, the company rating was maintained by SunTrust. The firm earned “Hold” rating on Thursday, June 8 by J.P. Morgan. The rating was upgraded by Piper Jaffray on Friday, October 30 to “Neutral”. Oppenheimer maintained the stock with “Hold” rating in Tuesday, August 29 report. The stock of Seattle Genetics, Inc. (NASDAQ:SGEN) has “Hold” rating given on Monday, June 19 by Cantor Fitzgerald. The rating was maintained by RBC Capital Markets on Wednesday, January 31 with “Buy”. As per Monday, October 10, the company rating was maintained by RBC Capital Markets.

Since August 24, 2017, it had 1 buying transaction, and 16 sales for $189.84 million activity. SIEGALL CLAY B also sold $1.01M worth of Seattle Genetics, Inc. (NASDAQ:SGEN) on Monday, September 11. Another trade for 25,000 shares valued at $1.31M was made by DOBMEIER ERIC on Thursday, August 31. BAKER BROS. ADVISORS LP bought $200.00 million worth of Seattle Genetics, Inc. (NASDAQ:SGEN) on Thursday, February 1. Another trade for 10,000 shares valued at $532,190 was made by HIMES VAUGHN B on Friday, September 8. 1,788 Seattle Genetics, Inc. (NASDAQ:SGEN) shares with value of $85,635 were sold by Cline Darren S. DRACHMAN JONATHAN G also sold $475,414 worth of Seattle Genetics, Inc. (NASDAQ:SGEN) on Thursday, August 24. Shares for $501,176 were sold by SIMPSON TODD E.

Investors sentiment decreased to 0.78 in Q3 2017. Its down 0.52, from 1.3 in 2017Q2. It is negative, as 51 investors sold SGEN shares while 74 reduced holdings. 29 funds opened positions while 69 raised stakes. 140.23 million shares or 2.00% more from 137.48 million shares in 2017Q2 were reported. Asset Mgmt One Ltd holds 0.03% of its portfolio in Seattle Genetics, Inc. (NASDAQ:SGEN) for 198,510 shares. Fjarde Ap reported 26,874 shares stake. University Of Notre Dame Du Lac invested in 55,319 shares or 0.84% of the stock. 19,600 were reported by Tributary Cap Mngmt Limited Liability Corp. Pathstone Family Office Limited Liability Corporation reported 0.02% of its portfolio in Seattle Genetics, Inc. (NASDAQ:SGEN). Bnp Paribas Arbitrage Sa owns 17,531 shares. Envestnet Asset invested in 1,567 shares or 0% of the stock. Mufg Americas Holding Corp accumulated 100 shares. 15.41 million are held by Baillie Gifford &. Primecap Ca stated it has 0.58% in Seattle Genetics, Inc. (NASDAQ:SGEN). Dekabank Deutsche Girozentrale holds 0.03% in Seattle Genetics, Inc. (NASDAQ:SGEN) or 84,337 shares. Royal State Bank Of Canada reported 201,280 shares. Pioneer Trust Retail Bank N A Or stated it has 0.28% in Seattle Genetics, Inc. (NASDAQ:SGEN). Rhumbline Advisers owns 0.01% invested in Seattle Genetics, Inc. (NASDAQ:SGEN) for 107,849 shares. Goldman Sachs Group owns 1.29M shares for 0.02% of their portfolio.

Among 19 analysts covering Paylocity (NASDAQ:PCTY), 12 have Buy rating, 0 Sell and 7 Hold. Therefore 63% are positive. Paylocity had 43 analyst reports since August 14, 2015 according to SRatingsIntel. The firm has “Buy” rating given on Thursday, February 8 by RBC Capital Markets. The firm earned “Buy” rating on Friday, November 3 by Needham. On Thursday, February 8 the stock rating was maintained by Stifel Nicolaus with “Buy”. The firm earned “Outperform” rating on Tuesday, March 28 by RBC Capital Markets. Stifel Nicolaus maintained Paylocity Holding Corporation (NASDAQ:PCTY) on Friday, May 6 with “Buy” rating. The stock of Paylocity Holding Corporation (NASDAQ:PCTY) earned “Equal-Weight” rating by First Analysis on Friday, July 8. The firm has “Outperform” rating given on Wednesday, August 9 by Raymond James. As per Monday, August 7, the company rating was maintained by Stifel Nicolaus. Robert W. Baird initiated Paylocity Holding Corporation (NASDAQ:PCTY) rating on Thursday, January 7. Robert W. Baird has “Outperform” rating and $44.0 target. Bank of America upgraded the shares of PCTY in report on Friday, February 3 to “Buy” rating.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: